Thursday, October 31, 2013

Birinyi Diverges From Einhorn Short Forecasting S&P 500 at 1,820

Two of America's best known investors are moving in opposite directions in the stock market, with Laszlo Birinyi predicting more gains as David Einhorn takes a more cautious approach.

Holdings that profit if stocks gain at Einhorn's Greenlight Capital Re Ltd.'s exceeded short bets by 35 percentage points as of Sept. 30, compared with about 42 percentage points three months earlier, he said today on a conference call.Birinyi, president of Birinyi Associates Inc., said the Standard & Poor's 500 Index will reach 1,820 by February and bought calls that profit from a rally in equity benchmark.

The divide is widening between Birinyi, whose bullish forecasts have proved prescient during a 4 1/2-year bull market, and Einhorn, who gained fame betting against Lehman Brothers Holdings Inc. Stocks in the U.S are in the midst of their broadest advance on record, a rally that has burned short sellers and pushed valuations to the highest levels since 2010 as the S&P 500 (SPX) reaches all-time highs.

"As the market continued its relentless climb, we've become more conservatively positioned," said Einhorn, a hedge-fund manager and chairman of Greenlight Re, a Cayman Islands-based reinsurer.

Stocks climbed this year as earnings exceeded analyst forecasts, unemployment declined and the Federal Reserve continued its economic stimulus program. The S&P 500 has gained 4.9 percent in October, bringing the advance for the year to 24 percent, the most since 2003. The advance has pushed the price-earnings ratio up almost 20 percent to 16.7, according to data compiled by Bloomberg.

Call Options

Birinyi predicts a 3.2 percent advance to 1,820 in the next three months, according to a report today. His firm purchased calls on the SPDR S&P 500 ETF Trust (SPY) with a strike price at $182 that expire in January 2014. The exchange-traded fund closed at $176.29 yesterday. The S&P 500 was little changed at 1,764.73 at 1:47 p.m. in New York.

Einhorn said most of the portfolio gain in the third quarter was from long holdings in companies including Apple Inc. (AAPL) He said he was sticking with his short positions, or wagers that a stock will decline, including one on Green Mountain Coffee Roasters Inc.

"The losses in the short book were broad-based, and we continue to be short most of the companies that contributed to the loss," he said. "These include a variety of companies which tend to have conventional valuations, rather than speculative story stocks that have caused excessive pain for other short sellers."

Investment Returns

Greenlight Re's investment portfolio returned 4 percent in the third quarter and 12 percent in the first nine months of the year, the company said yesterday in a filing. That compares with 5.2 percent and 20 percent for the S&P 500, including dividends. The reinsurer's portfolio was valued at $1.15 billion as of Sept. 30.

Einhorn, 44, has sounded alarms about the climb in asset prices for months. Last year he compared excessive stimulus by central bankers with eating too many jelly donuts, a habit that can be a threat to long-term health, according to an article that quoted him in Grant's Interest Rate Observer.

Birinyi's 1,820 forecast comes after he said in August the S&P 500 would reach 1,740 by the end of the year. He projected in January that the index had more than a 50 percent chance of reaching 1,600 in 2013. The gauge surpassed 1,600 in May and 1,740 this month.

Unexpected Obstacles

"We took it on a step-by-step basis expecting some detours and unexpected obstacles, which did occur," Birinyi wrote.

The S&P 500 has a 51 percent chance of reaching the new forecast by Jan. 31 and a 75 percent chance of doing so by March 31, according to today's note.

Birinyi has stuck to his bullish projections since the rally began. He said the bull market was intact in August 2011 when S&P's downgrade of the U.S.'s AAA credit rating helped send the index down almost 20 percent.

He cautioned investors not to "get shaken out" in May 2012, as stocks lost 9.9 percent. This year represents the fourth and final phase of the rally, during which gains accelerate as investors pile in, Birinyi said.

The index will drop to 1,718 by year's end, according to the average of 19 Wall Street strategist projections compiled by Bloomberg, whose estimates range from 1,440 to 1,800.

Benzinga's Top #PreMarket Losers

Ariad Pharmaceuticals (NASDAQ: ARIA) shares dropped 38.38% to $2.44 in pre-market trading on Iclusig marketing suspension.

NII Holdings (NASDAQ: NIHD) dipped 26.10% to $3.54 in the pre-market session after the company reported Q3 results.

Avon Products (NYSE: AVP) shares fell 11.42% to $19.85 in the pre-market trading after the company reported weaker-than-expected Q3 results.

Glu Mobile (NASDAQ: GLUU) dipped 10.29% to $3.40 on Q3 results.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Around the Web, We're Loving... Learn to Use Trading Platforms Like Hedge Fund Traders do Rumsfeld: Denial of Benefits to Fallen Soldiers' Families 'Inexcusable' Come See How the Pro's Trade in this Exclusive Webinar Facebook, Baidu Lead Big Caps Beating Shutdown What Should You Know About AMZN? Most Popular IBM Authorizes $0.95 Dividend; Authorizes $15B In Additional Buybacks What is Apple's Tim Cook Hinting at for 2014? Facebook Shares Edge Higher After Hours Following Upgrade to Buy from BTIG's Greenfield Is a Beer Mega-Merger On Tap? Earnings Scheduled For October 30, 2013 Net Optics Announces Pending Acquisition by Ixia for $190M in Cash Related Articles (ARIA + AVP) Benzinga's Top #PreMarket Losers #PreMarket Primer: Thursday, October 31: BOJ Bullish On Inflation Market Wrap for October 30: Fed Worries Push Stocks Lower, Facebook Earnings Raise Concerns Mid-Day Market Update: US Stocks Turn Lower; Electronic Arts Shares Rise On Upbeat Earnings Mid-Morning Market Update: Markets Open Higher; GM Profit Tops Estimates Benzinga's Top #PreMarket Gainers View the discussion thread. Partner Network #marketfy-ae-block { display: none; border: 2px solid #0a3f75; overflow: hidden; width: 300px; height: 125px; text-align: center; background-color: #45719E; position: relative; z-index: 1; } #marketfy-ae-block a { display: block; width: 300px; height: 125px; position: relative; z-index: 2; color: #ffffff; text-decoration: none; } #marketfy-ae-block-countdown-text { color: #f9fc99; padding: 0px 0 0 0; font-size: 19px; font-weight: bold; line-height: 19px; } #marketfy-ae-block-countdown-text-start { font-size: 12px; } #marketfy-ae-block-countdown { padding: 5px 0 5px 0; font-size: 26px; } #marketfy-ae-block-signup { padding: 5px 47px; } #marketfy-ae-block-signup:hover { background-color: #457a1a; } #marketfy-ae-block #marketfy-ae-block-logo { display: block; padding: 3px 0 0 0; margin: 0; } #marketfy-ae-block-logo { text-indent: -9999px; } #marketfy-ae-block-free { display: block; position: absolute; top: 7px; right: -23px; width: 80px; height: 16px; line-height: 16px; text-align: center; opacity: 1; -webkit-transform: rotate(45deg); -moz-transform: rotate(45deg); -ms-transform: rotate(45deg); transform: rotate(45deg); font-size: 13px; font-weight: normal; color: #333333; background-color: yellow; z-index: 500; text-shadow: 1px 1px #999999; } #marketfy-ae-block-arrow { position: relative; width: 60px; height: 60px; z-index: 10; margin: -80px 0 13px -21px; } #marketfy-ae-block-arrow img { height: 60px; width: auto; } Marketfy's International
Traders & Investors Summit Register for this FREE Event! Hosted by Marketfy

Wednesday, October 30, 2013

The Obamacare Stock Surge

The Affordable Care Act, commonly known as Obamacare, has been off to a shaky start, to say the least. Unresponsive websites, a government shutdown, bickering politicians, and finger-pointing have tarnished the president's signature legislation. Problems aside, the new public exchange is an opportunity for long-term growth: The ACA adds 30 million Americans to insurance rolls. Healthcare stocks have great potential to grow over the next two to five years as consumers use the exchanges -- that is, when the website gets fixed.

While the techies tinker with Healthcare.gov, health insurance stocks have surged. The five major health insurance companies -- WellPoint, UnitedHealth Group, Aetna, Cigna and Humana -- have increased more than 30% in 2013. The ACA has been good so far to these shares. Other companies within health care are poised to profit even more as a result of the ACA roll-out. Let's talk about three potential big winners now that the ACA is a reality.

Lannett  (NYSEMKT: LCI  )  has been very efficient developing and manufacturing generic pharmaceuticals. Lannett's sales are up 13% this year. As millions are active in the health care exchanges, generic drugs will become even more popular. The Congressional Budget Office estimates that Americans save $8 billion to $10 billion a year using generic drugs.Lannett has shown to be effective in dealing with government regulators -- something that many companies (JPMorgan Chase) have trouble doing. It completed an important step by successfully submitting an Abbreviated New Drug Application of Thalidomide capsules.

Thalidomide is controversial, but Lannett has developed the capsules to treat blood cancer. Many still remember Thalidomide as the cure-all drug for morning sickness that inadvertently caused infants to be born with deformities such as phocomelia. Thalidomide capsule sales topped $66 million in the second quarter of 2013, and Lannett wants to add a generic and safe product to meet demand. This stock -- just above $20 per share -- has a high P/E of 51, but as frugal consumers look to save money any and everywhere they can, generic drugs seem to be a compromise many seem willing to make.

AmerisourceBergen (NYSE: ABC  )  has a great program called Good Neighbor Pharmacy, which has received the top ranking in the J.D. Power National Pharmacy Study for 2013. This program won the award in 2010 and tied for the top ranking in 2011. The study surveys actual customers to measure customer satisfaction for both mail-order and brick-and-mortar pharmacies. AmerisourceBergen is on track to have double-digit sales through 2014. The ACA will only add to their sales since more Americans will have health care, presumably filling lots of prescriptions.

Not only has AmerisourceBergen mastered pharmacy retail; the company has been busy restructuring the business. AmerisourceBergen has approved a quarterly dividend increase ($0.21 per share), repurchased $401 million in common stock, and approved $750 million in more buybacks. AmerisourceBergen has a strong retail position, 3,400 award-winning Good Neighbor Pharmacy stores,  and seems genuinely committed to investor earnings.

Universal Health Services (NYSE: UHS  ) has aggressively attacked a grown concern in America: diabetes. The company is currently developing specialty services to treat type 1 diabetes and mental health. Universal Health Services provides expert home, hospice and personal assistance care. They specialize in providing nurses who are skilled in diabetes and disease management. 

As those continue to be issues Americans deal with, Universal Health Services will increasingly be the health care solution many turn to. Not only has Universal Health Services created products and services that are timely and effective, the company has also made some shrewd investments -- such as the $190 million electronic health records implementation for the firms acute care hospitals -- that are ripe for profits.

Universal Health Services has successfully integrated Ascend Health, which it acquired in 2012. Universal Health Services has also agreed to pay a dividend of $0.05 per share. This company has all of the bases covered -- great M&A, timely and effective services, health centers, surgical hospitals -- and the ACA is the icing on the cake. Universal Health Services is uniquely positioned to grow because of the ACA. The company has more reach than drugmakers and hospitals because they provide much-needed services in consumers' homes. Universal Health Services can effectively compete against large regional hospitals via its 226 ambulatory surgery centers, behavioral health facilities, and acute care hospitals.

Don't let fear come between you and profits. The ACA is new, and is much maligned, but it is the law. Capitalize on it. Don't hate -- profit.

Get your Obamacare questions answered
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called Everything You Need to Know About Obamacare. But don't hesitate; because it's not often that we release a FREE guide containing this much information and money-making advice. Please click here to access your free copy.

Tuesday, October 29, 2013

Americans' Confidence in Economy Plummets Amid Shutdown

Consumer Confidence (In this Friday, Oct. 4, 2013, photo, a shopper browses at a Timberland store in Skokie, Ill. The ConferenceNam Y. Huh/AP WASHINGTON -- Americans' confidence in the economy fell this month to the lowest level since April, as many worried about the impact of a 16-day partial government shutdown. The decline could weigh on spending and economic growth. The Conference Board said Tuesday that its index of consumer confidence dropped to 71.2 in October, down from 80.2 the previous month. September's figure was revised slightly higher. Consumers became particularly pessimistic in their outlook on the economy six months from now, while their assessment of current economic conditions declined by much less. They also expect less hiring in the months ahead. Consumer confidence is closely watched because their spending accounts for 70 percent of economic activity. Americans became more confident in the spring as job gains were healthy and economic growth improved. The Conference Board's measure reached 82.1 in June, the highest in 5½ years. That's still below the reading of 90 that is consistent with a healthy economy. Confidence has dropped in three of the four months since June. The shutdown already caused a drop this month in the University of Michigan's measure of consumer sentiment. Americans made more negative references to the federal government's impact on the economy in October than at any time in the 50-year history of the survey, the university said. Falling confidence can cause Americans to spend less, which would slow the economic growth. But sometimes consumers spend more, even when they say they are less confident. Weaker job growth is also weighing on consumers' outlook. Employers added an average of just 143,000 jobs a month from July through September. That's down from 182,000 a month in April through June and 207,000 in the first three months of the year. Sluggish spending is likely to weigh on economic growth. Most economists predict growth slowed in the July-September quarter to an annual rate of about 1.5 percent to 2 percent, down from a 2.5 percent rate in the April-June quarter. And the shutdown is likely to keep growth at a tepid pace for the final three months of the year.

Monday, October 28, 2013

In With This, Out With That (TSLA, DGLY)

There's no denying Tesla Motors Inc. (NASDAQ:TSLA) has been one of year's top investment stories, with shares running up from less than $40 to more than $194 in just a few short months. But, as one might imagine, that 385% runup from TSLA creates something of a disconnect between the company and its share price. Time to head for the exit. Instead, a better use of that now-considerably-greater capital is a position in Digital Ally, Inc. (NASDAQ:DGLY) ... a stock that's also had a pretty good 2014, but has suffered more than a small setback since mid-September. Specifically, DGLY has pulled back from a peak price of $17.47 to a low of $9.88 as of Friday. But, it looks like that correction may have already come to an end.

First and foremost, know that neither of these calls on TSLA or DGLY are long-term outlooks, nor judgment calls on the merit of either company. Tesla Motors remains one of the coolest (and only viable) electric vehicle manufacturers out there, and though Digital Ally makes some of the best security-related technology in the world, it's not as if the company is bulletproof. On the other hand, the brewing moves from either of these stocks could be too big for even long-termers to simply ignore, miss, or ride out.

The red flags for Tesla Motors may be simple, but sometimes the simplest clues are the most reliable. Specifically, TSLA shares have now logged two lower highs while also en route to two lower lows. During this time, the stock has also rocked its way not only under the 20-day moving average line (blue), which had been support all during the rally, but also under the 50-day moving average line (purple) as of last week. In fact, though it looked as if TSLA might have fought its way back above the 50-day moving average line late last week, with today's weak open it's become clear the bulls just don't have what it takes to push this rock up the hill again, now that so much technical damage has been done; there's a lot of "white space between $168 and $99 too, pulling the stock lower.

As for Digital Ally, yes, it may be in the red today after reversing course from a strong open. But, the bulls seem to have tipped their hand on Friday by brushing the key 100-day moving average line and immediately reversing course. Better still, even with today's pullback from DGLY - and maybe even more so because of it - the chart has made it clear it's holding the line at the 100-day moving average line at $10.40.

Again, neither of these calls is a long-term call. They're just trading calls, so don't get married to in Digital Ally, Inc., and don't plan on holding a bet against Tesla Motors Inc. for too long either. But, both potential moves are big enough to note, worry about, and even act upon.

If you'd like to receive more trading ideas and insights like this one, you want to subscribe to the free daily SmallCap Network e-newsletter.

Sunday, October 27, 2013

Does Procter & Gamble Support Rising Prices Post-Earnings?

With shares of Procter & Gamble (NYSE:PG) trading around $79, is PG an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Procter & Gamble engages in the manufacture and sale of a range of branded consumer packaged goods. The company operates in five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The products provided by Procter & Gamble are my regarded as essential to a large segment of the worldwide population. As populations continue to grow and adopt its products and as a leading provider, Procter & Gamble stands to see rising profits for many years. Worldwide demand for Procter & Gamble products will continue to drive profits for this huge conglomerate.

The stock reported earnings before the opening bell October 25, 2013, posting earnings per share of $1.05 and $21.21 billion in revenue, which are relatively in line with expectations. Jon Moeller, the company's CFO, was optimistic about the data, saying that he expects full-year adjusted earnings to rise to 7 percent growth in the second half of the year. The markets took in the news with a lukewarm attitude, with the shares trading down slightly after digesting the report. Not surprising, considering that the stock is already trading near all time highs.

T = Technicals on the Stock Chart are Strong

Procter & Gamble stock has been moving higher in the last couple of years. The stock is currently trading near all time high prices but may need a little more time at current prices. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Procter & Gamble is trading slightly above its rising key averages, which signal neutral to bullish price action in the near-term.

PG

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of Procter & Gamble options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

Procter & Gamble Options

16%

0%

0%

What does this mean? This means that investors or traders are buying a very minimal amount of call and put options contracts as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

November Options

Flat

Average

December Options

Flat

Average

As of today, there is an average demand from call buyers or sellers and low demand by put buyers or high demand by put sellers, all neutral to bullish over the next two months. To summarize, investors are buying a very minimal amount of call and put option contracts and are leaning neutral to bullish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on Procter & Gamble’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for Procter Gamble look like and more importantly, how did the markets like these numbers?

2013 Q3

2013 Q2

2013 Q1

2012 Q4

Earnings Growth (Y-O-Y)

8.33%

-19.85%

7.32%

143.90%

Revenue Growth (Y-O-Y)

2.25%

0.86%

2.00%

1.98%

Earnings Reaction

-1.34%*

1.66%

-6.56%

4.01%

Procter & Gamble has seen increasing earnings and revenue figures over the last four quarters. From these numbers, the markets have had mixed feelings about Procter & Gamble’s recent earnings announcements.

* As of this writing

P = Weak Relative Performance Versus Peers and Sector

How has Procter & Gamble stock done relative to its peers, Johnson & Johnson (NYSE:JNJ), Kimberly-Clark (NYSE:KMB), Colgate-Palmolive (NYSE:CL), and sector?

Procter & Gamble

Johnson & Johnson

Kimberly-Clark

Colgate-Palmolive

Sector

Year-to-Date Return

17.81%

31.26%

24.40%

21.25%

24.68%

Procter & Gamble has been a poor relative performer, year-to-date.

Conclusion

Procter & Gamble provides a variety of essential products to consumers in a multitude of countries around the world. A recent earnings release has investors expecting a little more from the company. The stock has been moving higher in recent years and is now consolidating near all time high prices. Over the last four quarters, earnings and revenues have been on the rise, however, investors have had mixed feelings about the company. Relative to its peers and sector, Procter & Gamble has been a weak year-to-date performer. WAIT AND SEE what Procter & Gamble does at current prices.

Friday, October 25, 2013

Green is the Warmest Color: S&P 500 Finishes Week at Record High

It’s slim pickings at the box office this week. Moviegoers could take in Jackass Present: Bad Grandpa, the Johnny Knoxville flick about a bad grandpa traveling cross-country with his grandson. While it could take in $25 million this weekend, I’m guessing not much of that will come from Barron’s readers. Then there’s the Cormac McCarthy-scripted the Counselor, which has gotten terrible reviews, despite a cast featuring Penelope Cruz, Cameron Diaz and Brad Pitt. And for those of us who dig the art house, there’s Blue is the Warmest Color, the winner of the  Palme D’Or at Cannes this year, but that’s playing in only four theaters and is surely not to everyone’s taste.

Investors had a little better luck this week, as plenty of stocks were on the move. Boeing (BA), for instance, was the big winner in the Dow Jones Industrial Average after it gained 7.1% to $131.19 this week following a big earnings beat thanks to big profits from its commercial aircraft division. Alexion Pharmaceutical  (ALXN), meanwhile, was the biggest non-tech gainer in the S&P 500, with a 15% gain to 125.17. It beat earnings and had a drug designated fast-tracked for approval. And over in the S&P 1500, Career Education Corp. (CECO) gained 91% to $5.98 after selling its European schools for more than its market cap.

It wasn’t all good news, however. Healthways (HWY) plunged 30% to $11.41, making it the S&P 1500′s biggest loser, while Cameron International (CAM) fell 18% to $53.25, making it the S&P 500′s weakest stock. Both released disappointing earnings reports this week.

Still, the Dow Jones Industrials rose 1.1% to15,570.28 this week, while the S&P 500 gained 0.9% to 1,759.77, a record high. The new highs had some bears proclaiming that stocks are expensive. MRB Research Partners doesn’t buy it. They write:

Stocks offer average value in absolute terms and good value relative to bonds and short-term interest rates. Stay long equities: an upmove to at least moderately overvalued levels should occur before the bull market ends, given plentiful liquidity conditions, improving economic activity and lagging central bankers, and the lack of attractive alternatives (the love affair with gold and commodities has waned, and the demand for bonds is now ebbing as well).

Next week brings data galore–industrial production and pending home sales on Monday, retail sales on Tuesday, among others–but don’t expect the Fed to act on it when it meets, says Pierpont Securities’ Stephen Stanley. He writes:

This week brings a heavy slate of events, but with the data mostly distorted and the FOMC not likely to budge any time soon, the impact of the data will be limited…the FOMC meeting this week will likely come and go without much fanfare.  There will be no press conference, and the statement may have only cosmetic changes.  In my view, the FOMC is not going to seriously contemplate tapering until March 2014 at the earliest.

Meet the new risk regime, same as the old regime.

Thursday, October 24, 2013

BART Workers Won: Will Your City's Employees Strike Next?

Rapid Transit Walkout Resumes, Threatening ChaosGetty Images Following almost four days of closures, Bay Area Rapid Transit trains started operating again Tuesday morning, after representatives for striking BART union workers reached a tentative deal with BART management on Monday night. And although both sides still must formally approve the agreement, workers appear to have won a 15.38 percent raise over their four-year contract, in exchange for concessions that include an increase in their monthly medical insurance premiums of about $50, and agreeing to start contributing a portion of their pension costs. The BART strike is just the latest example of clashes between state and local government employees and the cash-strapped cities, counties, and states that employ them. Newly energized by what many will see as a win, government workers around the country might well follow suit in efforts to defend themselves against a rising tide of municipal bankruptcies and other financial threats to their security. Cities Under Siege Just 90 minutes east of San Francisco, the city of Stockton, Calif., is just one of many local governments dealing with huge financial problems. Last year, Stockton became the largest city in the U.S. to file for bankruptcy, holding that dubious honor until July 2013, when Detroit took the crown. In Stockton, current and retired city workers have found themselves at the forefront of controversy over the rights of government employees. The city has trimmed its workforce by about 30 percent, with dramatic reductions even to essential services such as its police department. However, Stockton's proposed bankruptcy plan last month included full payments to the California Public Employees' Retirement System, thus pitting pension recipients against municipal bond investors and insurance companies, as well as other creditors of the city. Not so say those retirees will get off unscathed: Health benefits promised to former city employees will be affected by the bankruptcy. But some say that even with that concession, the plan unfairly favors former workers at the expense of both current workers and other interested parties. Showdown in Motown Meanwhile, in Detroit, officials have laid even more of the blame for the city's financial troubles at the feet of former government employees. A report last month from The New York Times showed that retired city workers actually received billions of dollars in extra pension payments. Even some current employees received supplemental income, and families of deceased workers sometimes received cash payments according to the report. Outside analysis by actuarial experts found that these excess payments to workers, retirees, and their families cost Detroit almost $2 billion between 1985 and 2008. More broadly, state and local governments clearly benefited from the strong economies of the 1990s and mid-2000s, with investment gains bolstering pension plans and rising property values bringing in more tax revenue. Yet home prices and the stock market both plunged in the late 2000s, and that eliminated any financial cushion that state and local governments enjoyed prior to the Great Recession. More Struggles to Come As governments and government workers draw battle lines in their respective states, cities, and towns, many are waiting for the next shoe to drop. Harrisburg, Pa., tried to file for bankruptcy protection, but its request was denied. Pennsylvania's insolvent capital city continues to work on its finances through a receivership proceeding; the latest proposal to lift it out of the hole involves leasing out its parking system and selling a power plant that converts waste to energy. In California, Fresno has faced credit-rating downgrades that cite its weak finances after expansion plans that didn't pan out as well as local officials had hoped. The Philadelphia School District had to borrow $50 million just to open its schools on time this year, and with a deficit of more than $300 million in its $2.35 billion budget, the district hopes to get workers to agree to cuts in pay and benefits under their labor contracts in order to close the gap. Still, the pressure on governments to find ways to keep essential services running is immense. As a result, it's easier for government officials to make decisions that are geared more toward short-term patches rather than long-term solutions. In the wake of the BART strike, more state and local government employees might recognize the leverage they have, only increasing the difficulty that government entities face in balancing the needs of their constituents against the limited financial resources of their taxpayers. Your city might well be the next to see government employees take action to defend themselves against the next swing of the budget ax.

Is Broadcom Oversold At Current Prices?

With shares of Broadcom (NASDAQ:BRCM) trading around $26, is BRCM an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Broadcom provides semiconductor solutions for wired and wireless communications. Its products offer voice, video, data, and multimedia connectivity in the home, office, and mobile environments. The company operates in three segments: Broadband Communications, Mobile and Wireless, and Infrastructure and Networking. Broadcom markets and sells its products through direct sales force, distributors, and manufacturers' representatives in the United States and through regional offices, as well as a network of independent and fulfillment distributors, and representatives primarily in Asia, Australia, Europe, and North America.

Broadcom reported financial results for its third quarter ended September 30, 2013 that did not impress investors. ”Broadcom delivered better-than-expected results across the board in the September quarter,” said Scott McGregor, Broadcom’s President and Chief Executive Officer. “With the Renesas transaction closed, the combined team is working diligently to deliver LTE revenue in early 2014. Looking forward, we are taking the necessary steps to tightly manage the business while focusing on strategic initiatives, including LTE, data center innovation and driving the next generation of home video with HEVC.”

T = Technicals on the Stock Chart Are Mixed

Broadcom stock been declining in the last several years. The stock is currently trading near lows for the year so it may need time at current prices. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, Broadcom is trading between its key averages, which signal neutral price action in the near-term.

BRCM

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of Broadcom options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

Broadcom Options

31.42%

36%

35%

What does this mean? This means that investors or traders are buying a small amount of call and put options contracts as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

November Options

Steep

Average

December Options

Steep

Average

As of today, there is an average demand from call buyers or sellers and high demand by put buyers or low demand by put sellers, all neutral to bearish over the next two months. To summarize, investors are buying a small amount of call and put option contracts and are leaning neutral to bearish over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on Broadcom’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for Broadcom look like and more importantly, how did the markets like these numbers?

2013 Q3

2013 Q2

2013 Q1

2012 Q4

Earnings Growth (Y-O-Y)

-3.80%

-253.57%

120.00%

-4.92%

Revenue Growth (Y-O-Y)

0.85%

6.04%

9.74%

14.29%

Earnings Reaction

-3.39%*

-15.14%

6.36%

0.47%

Broadcom has seen decreasing earnings and increasing revenue figures over the last four quarters. From these numbers, the expected more from Broadcom’s recent earnings announcements.

* As of this writing

P = Weak Relative Performance Versus Peers and Sector

How has Broadcom stock done relative to its peers, Qualcomm (NASDAQ:QCOM), Texas Instruments (NASDAQ:TXN), NVIDIA (NASDAQ:NVDA), and sector?

Broadcom

Qualcomm

Texas Instruments

NVIDIA

Sector

Year-to-Date Return

-20.80%

8.89%

28.49%

26.51%

10.25%

Broadcom has been a weak relative performer, year-to-date.

Conclusion

Broadcom provides wireless and wired semiconductor technologies to businesses and consumers worldwide. A recent earnings release has investors disappointed with the company. The stock has struggled in recent years and is currently trading near lows for the year. Over the last four quarters, earnings have decreased while revenues have increased, which has left investors to expect more from the company. Relative to its peers and sector, Broadcom has been a weak year-to-date performer. WAIT AND SEE what Broadcom does this coming quarter.

Wednesday, October 23, 2013

Microsoft Tries to Avoid Another Hardware Failure

Facing lackluster performance from the Microsoft (NASDAQ: MSFT  ) Surface RT and Surface Pro, the company is hoping that, by turning to businesses through resellers like CDW, sales can improve. The Microsoft-branded tablets face stiff competition from both Apple and Google, and sales figures have shown it. In addition to opening distribution channels, Mr. Softy is rolling out a program to encourage developers to work on new apps in an effort to become more competitive.

In the video below, Fool.com contributor Doug Ehrman examines the move by Microsoft, and how it positions the company heading into the second half of the year.

It's incredible to think just how much of our digital and technological lives are almost entirely shaped and molded by just a handful of companies. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks?" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.

Tuesday, October 22, 2013

Electric car prices decelerate

electric car

GM took $5,000 off the price of a rechargeable Chevy Volt.

(Money Magazine) Electric car prices have gotten shockingly reasonable.

In August, GM took $5,000 off the $40,000 price of its rechargeable Chevy Volt. Thank California, which has passed sales quotas for eco-friendly vehicles -- and helped spark a price war.

If you buy an electric, a $7,500 federal tax credit brings the cost down to little more than a similar gas-powered car. And leases are cheap too.

The brightest electrics

Chevrolet Volt. Worried that you might run out of juice? The gas engine kicks in after 38 miles. Biggest downside: The car seats only four.

Sticker price: $34,995

Lease: $299 a month for 36 months, $2,499 down

Range per charge: 38 miles (another 343 on gas)

Nissan Leaf. This fun-to-drive five-seater has sufficient range for most daily needs, and can save you $1,000 a year in fuel costs vs. a comparable car. "It's surprisingly cheap to commute on electricity," says Edmunds.com senior editor (and Leaf leaser) Phil Reed.

Chevy Spark EV: Greener, faster, better   Chevy Spark EV: Greener, faster, better

Sticker price: $29,650

Lease: $199 a month for 36 months, $1,999 down

Range per charge: 83 miles

Tesla Model S. Its price is near that of a full-size BMW, its crash test rating is stellar, and its performance is, well, electric.

"The acceleration is just amazing," says ClassicCars.com CEO Roger Falcione, a new Model S owner.

Sticker price: $69,900

Range per charge: 208 miles To top of page

Monday, October 21, 2013

Mismatched Legal Developments Lead to Bank of America Slide

As the overall market takes a breather from its three-day rally, investors appear to be heading into the weekend in the red. So too is Bank of America (NYSE: BAC  ) this morning, down 1.1% at 10:30 a.m. EDT. Though it may be following the pack as we close out the quarter, some new legal developments may also be pushing the bank further into negative territory.

Good news first
In a move that will likely help the bank stay away from litigation, a group of state and federal officials have notified the New York Attorney General's office that no enforcement action will be taken against B of A or Wells Fargo (NYSE: WFC  ) for violations of last year's $25 billion mortgage settlement terms. The NYAG had notified the states and the settlement's overseer that it intended to file suit against the banks for the violations, but it had been temporarily stymied by the banks' request for time to cure the alleged missteps.

Now, the stance of the federal and state parties that there will be no enforcement action takes some of the wing out from beneath the AG's wings. The latest from the Attorney General's office had cited numerous violations as reported by these other states as reason to press forward with the intended suit. But the current stance of the states and federal parties is to allow the banks to remedy the violations with homeowners directly, with the belief that reform of the process will come faster if litigation is avoided.

Though this is a win for B of A in that it may keep the bank out of the courtroom, it pales in comparison to the scale of the bank's other prominent legal battle.

Questionable news
Based on a letter filed by American International Group (NYSE: AIG  ) , Bank of America refused new negotiations over its $8.5 billion settlement with investors following a suggestion by the judge presiding over the settlement hearing that the bank and investors should try mediation to determine the fairness of the settlement. This suggestion was given in a private meeting earlier in the month, before the hearing was put on hold because of the judge's heavy caseload.

The bank is confident that the hearing will be resolved in its favor, so mediation could be counter-productive and cost the bank more than the stated $8.5 billion. But for those with less confidence, the potential $60 billion price tag could prove to be troubling.

Bank of America has had a tough climb with all of its legal troubles weighing it down, but as a Foolish long-term investor, you have to decide if the bank's fundamentals are strong enough to carry it despite the added forces pulling it down.

Sunday, October 20, 2013

PSivida: Thoughts In The Aftermath Of The Complete Response Letter On Iluvien

Background on the Complete Response Letter

This note focuses on the implications of the complete response letter (CRL) received by Alimera (ALIM) for Iluvien. This product was developed by pSivida (PSDV) but was partnered with Alimera. This report deals only with the investment significance for pSivida.

Alimera announced that it had received another CRL from the FDA on the resubmission of the Iluvien NDA. This follows two previous CRLs received on 12/23/10 and 11/11/11. The CRL appeared to be the result of FDA concerns about the benefit/risk of Iluvien. The agency indicated that in order to satisfy its concerns that Alimera would have to conduct a new trial with at least 12 months of follow-up. It seems highly unlikely that Alimera would consider doing a new phase III trial in diabetic macular edema (DME). The trial might take three to four years to complete and a financially strapped Alimera probably lacks the financial resources to conduct such a trial.

Could Iluvien Yet Receive Approval for Pseudophakic Patients?

The situation looks completely black except for one little ray of hope. The FDA has said that it will convene an FDA advisory committee on Iluvien on January 27, 2014. This is highly unusual in the aftermath of issuing a CRL and like many other investors I am scratching my head on this. In grasping for an explanation I came up with this hypothesis. The side effect issues with Iluvien as shown in pivotal FAME trials were elevated intra-ocular pressure that caused the use of eyedrops in about 38% of the Iluvien patients as compared to 14% in the control group. Cataracts occurred in 80% of the Iluvien treated patients as compared to 46% in the control arm.

I think the data in FAME clearly supports the effectiveness of Iluvien in diabetic macular edema. Let's hypothesize that the FDA believes Iluvien is effective and is willing to accept the risk of elevated intra-ocular pressure so that its concerns center on the high rate of cataract formation. If that i! s the case, there is a sub-group of pseudophakic patients who have had their natural lenses removed and replaced with an artificial lens. Without their natural lenses, they would not be at risk of cataract formation. Also, Alimera has shown subset data that suggests that Iluvien is very effective in that patient population. This then could be a group of patients in which the benefit/risk is very positive.

There is some chance that the purpose of the FDA advisory committee is to evaluate whether Iluvien should be approved for pseudophakic patients. If so, the next question to ask is whether the FDA might decide to approve Iluvien on the basis of existing data. It would be highly unusual for the FDA to approve a drug based on a retrospective analysis of a patient sub-group even if the AdCom felt that the benefit/risk was positive; the FDA might still require a new trial. I can't place high probability on the FDA approving Iluvien for pseudophakic patients on the basis of existing data, but I think that I want to hold my stock until I can judge the outcome of the AdCom meeting.

From the standpoint of pSivida , this raises some possibility of the positive scenario yet being achieved. As you may recall, pSivida is developing its proprietary drug Medidur for the condition of posterior uveitis; it uses the same active pharmaceutical ingredient, same dosage and same delivery vehicle as Iluvien. If Iluvien is approved, pSivida would receive $25 million and as importantly it could speed the approval of Medidur as explained below. The US addressable market for Medidur in posterior uveitis could be on the order of $360 million, roughly the same magnitude as Iluvien in DME.

The approval of Iluvien for pseudophakic patients would trigger the bull case of the immediate payment of $25 million, which would put pSivida in an extremely comfortable cash position. Also, the post marketing clinical experience with Iluvien might give the FDA sufficient understanding of the long-term safety profile of Iluvien! to appro! ve Medidur with just one phase III trial.

I think that approval of Iluvien is the most positive outcome for pSivida, but interestingly, I have hear a counter argument that takes the position that non-approval might be more positive by improving its long-term prospects. The rationale is that if Medidur is approved, it would get the entire posterior uveitis market plus off label use in DME. I can see some merit in this argument, but think that approval of Iluvien is a more positive outcome.

Implications for Medidur

pSivida has just started the first of two planned phase III trials for Medidur; it will enroll 120 patients. According to ClinTrials.gov the study should complete by July of 2015 so that topline efficacy data could be available in late 2015. The study also requires a three year safety follow-up on patients that could be completed in July 2017. The second phase III will enroll 180 patients and would probably start in 2H 2015 and I would expect efficacy topline data in 2H 2017. I think that the company could file an NDA if the primary efficacy endpoint is reached in both trials. This assumes that the FDA would be comfortable with the safety follow-up data from the first 100 patients in the phase I trial and could result in approval in 2018.

The FDA would normally ask for safety data on significantly more patients than the 300 patients involved in the phase III trials of Medidur. I initially thought that the Medidur NDA could reference the Iluvien safety data base only if Iluvien was approved. This would have required more than 300 patients and the second phase III would have to be significantly larger than 180 patients. However, in a new and positive development at a recent meeting with the FDA, the agency indicated that PSDV could use the existing Iluvien data base for safety in support of the posterior uveitis indication being sought by pSivida, even if Iluvien is not approved; this is a major positive for Medidur that I had not anticipated in my earlier reports.

T! here is s! ome chance that if Iluvien could be approved on the basis of one phase III trial if the results are striking and if the FDA believes that it understands the safety profile of Medidur, which would be in part based on the Iluvien safety database. With this optimistic scenario, Medidur could be filed in 2016 and receive approval in 2017. If the FDA requires two trials, approval could be received in 2018. Again, I had originally thought that approval on the basis on only one phase III trial could only occur with approval of Iluvien. I now think that there is some chance of approval based on one phase III trial regardless of Iluvien approval. Let me emphasize that there is a much greater chance for the FDA to require two phase III trials and this is what pSivida has planned for.

Tethadur Could be A Catalyst for pSivida

In regard to possible stock performance, other than the "Hail Mary" potential for Iluvien approval for pseudophakic patients, the possibility of which we could know in January or February of 2014, there is still one other potentially important catalyst sometime in the next six months or year for pSivida that relates to its new drug delivery technology Tethadur. Let me say from the outset that it is difficult for me to evaluate the potential of Tethadur as it is still in the pre-clinical stage.

Tethadur is porous silicon that has a honeycomb structure that can be formulated in particles with controllable properties of porosity, oxidation and dissolution. The material has a high affinity for proteins and the pores of this nanostructure can be designed to fit a target protein. pSivida has indicated that 1 cm3 of porous silicon (sugar cube size) has a surface area equivalent to a tennis court. The pore size can be controlled over a wide range and surface chemistry can be adjusted to facilitate loading of most biological drugs and provide sustained drug release. The resultant product is bioerodible so that no residue is left in the body. A biological drug can be lyophili! zed (drie! d into a powder). Water is then added to the lyophilized drug and the solution is drawn into a syringe that is pre-loaded with the appropriate Tethadur formulation. After waiting for a few minutes to allow the drug to distribute through the Tethadur formulation, the contents of the syringe are then injected.

The Tethadur technology is potentially applicable to any biological drug and may have a significant opportunity in the development of biosimilars to current large selling products; it may improve the performance of those drugs through sustained release. Of particular interest is that pSivida has said that it has a fully funded agreement with a major biotechnology company to evaluate the potential for sustained release of a major product to the back of the eye. The initial agreement is for the pre-clinical setting. pSivida has not said what the drug is, but speculation naturally centers on Regeneron's (REGN) Eylea or Roche's (RHHBY.OB) Lucentis. These drugs are enormously successful for the treatment of "wet" AMD but must be must be injected into the eye on a monthly or six week time frame.

If Tethadur could provide a less frequent injection schedule of say three to six months for either Eylea or Lucentis and retain the efficacy of these drugs, most of their combined sales could transfer very quickly to the Tethadur based product. This is a very significant opportunity as I estimate that Lucentis will achieve worldwide sales of $1.9 billion in 2013 and that Eylea's worldwide sales will reach $1.4 billion. At this point, this is something of a dream. However, if pSivida were to announce a licensing deal for clinical development of Tethadur for this purpose, I think that it could cause a major move in the stock. At this point, the odds of this happening are very difficult to predict.

Financial Considerations

If Iluvien is not approved, pSivida remains in a reasonable cash position as I estimate that it currently has about $19 million of cash. With a quarterly burn rate! of $2.0 ! to $2.5 million, PSDV has the cash resources to last until mid-2015, which would allow investors to see the topline results of the first phase III trial of Medidur and potential developments with Tethadur. In this two year period there could be payments from Iluvien sales in Europe and licensing deals for Tethadur that bring in meaningful amounts of cash so that the company might not have to do an equity financing. I do not anticipate the need for any sizable equity offering in this period. With success in that trial, PSDV should be able to raise capital on reasonable terms to conduct the second phase III trial for Medidur.

So what would I do with the stock?

At current price levels, I want to hold on to my stock. As we approach the January 27, 2014 AdCom meeting, I think that the stock might trade up from current levels on anticipation of the possibility of Iluvien approval in pseudophakic patients.

In the event that Iluvien is not approved, I don't see the risk of needing to finance out of desperation and there is reasonable, possibly quite exciting, new product potential. The upside for the stock would relate to developments with Tethadur, results for which are highly conjectural at this time. A licensing deal for Tethadur with either Lucentis of Eylea could be a major upside catalyst.

I don't see the stock as having much downside risk without US approval of Iluvien over the next two years as we wait for the Medidur phase III data and news on Tethadur. However, barring some truly striking event related to Tethadur, I wouldn't see the stock as having much upside either.

Source: PSivida: Thoughts In The Aftermath Of The Complete Response Letter On Iluvien

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. (More...)

Saturday, October 19, 2013

Wednesday's Top News Headlines

Here are today's top news headlines from Fool.com. Check back throughout the day as this list is updated, and follow us on Twitter at TMFBreaking.

Standard & Poor's Lowers Credit Outlook for JPMorgan Chase

Travelzoo Plans to Shake Out Small Shareholders

JetBlue May Traffic Jumps 9.4%

AuRico Gold Initiates Drip Program

AuRico Gold Executive Chairman Resigns for Health Reasons

Lead Director of Cliffs Natural Resources Resigns

ECB Official Defends Bond Purchase Plan

Abbott Launches Japanese Stent Trial

U.S. Chief Executives More Optimistic About Hiring

FDA Approves 2 St. Jude Heart Devices

TJX Companies Shareholders Elect New Member to Board of Directors

Northrop Grumman Gets New Chief Executive in Australia

Mindray Medical Appoints New Co-CEO

GE Moves Its CFO to Lead GE Capital

Oil Rises to $96, Reverses 2 Days of Losses

Facebook Opens 100% Hydroelectric-Powered Data Center in Sweden

PetSmart Names Non-Executive Chairman of the Board

Indian Company to Buy Cooper Tire for $2.5 Billion

Sirius Tops 10,000 Used-Car Partners

Walgreen to Pay $80 Million to Settle Federal Allegations Over Painkiller Distribution

Dunkin' Brands Expanding in Texas

Ruby Tuesday Gets a New Concept President

Crude Oil and Gasoline Inventories Rise

U.S. May Deficit Hits $139 Billion

Record Crop Forecast Sends Corn Prices Lower

3D Systems Buying Phenix Systems


Friday, October 18, 2013

3 Buy-Now Stocks from the "World's Greatest Retirement Portfolio"

Two years ago, I identified 10 companies that I would be putting $40,000 of my own retirement money behind. This was, has been, and will continue to be my way of helping the world to invest better.

Since then, that sum of money has grown to $54,280 -- a 35.7% increase, and $2,040 better than if I had just invested the money in the S&P 500.

Every month, I look over these stocks to see which three are tempting. I call these my "Buy Now" stocks because I think they're pretty good deals.

Read the chart below to see how the whole portfolio has performed, check out my best buys and, at the end, I'll offer up access to a special premium report on one of the 10 stocks.

Company

Publication Date

Change

Vs. S&P 500 (percentage points)

Google (NASDAQ: GOOG  )

6/26/11

80.8%

47

Pricesmart 

6/28/11

71.8%

40

Baidu (NASDAQ: BIDU  )

9/15/12

(12.3%)

(42)

Intuitive Surgical 

7/25/11

24.6%

(3)

National Oilwell Varco (NYSE: NOV  )

7/28/11

(12%)

(43)

Coca-Cola 

6/21/11

27.7%

(4)

Whole Foods 

7/5/11

69.3%

42

Amazon 

7/12/11

28%

(2)

Apple

6/30/11

37.5%

8

Johnson & Johnson 

8/1/11

41.4%

9

       

Total

 

35.7%

5.0

Source: YCharts

Though it's important to keep a long-term horizon, it's also worth noting that these "best buy" lists can quickly yield great results. For instance, had you bought the three stocks I suggested in May of 2012, you'd be sitting on average returns of 32%, far outpacing the S&P 500's return of just 19% since then!

So, without further ado, here are my three picks for June:

Google
Yes, Google stock has appreciated almost 50% over the past year. But this company has everything I look for in a buy-and-forget holding: top-notch management, a moat as wide as can be, and a culture of innovation that could create multiple profitable futures.

While some scoff at Google's latest experiments with computing glasses, I think its reasonable to assume that wearable technology will be the next frontier for personal computing. Even if Glass isn't a raging success, the fact that the company is innovative and willing to work on such products lets me know that people will continue using Google's search engine --which is really what drives revenue -- for years to come.

Long term, Google is trading hands at 16 times expected 2014 earnings. That seems like a fair price for one of the world's best companies.

Baidu
I'm waiting for someone to hit me over the head for continuing to put Baidu on this list month after month. Indeed, the stock has lost 18% of its value over the past year, and I've been recommending it all the way down.

Why do I continue to do so? Because I believe that, while some concerns pushing the stock down are legitimate, they are short term in nature. First is the concern about Qihoo 360. Though the fiery start-up has managed to capture 15% of China's search market, Baidu has the lion's share of the rest.

Furthermore, as Baidu is spending the money now to build out the type of infrastructure and mobile strategy that will keep it relevant for years to come, Qihoo simply doesn't have the financial resources to match what Baidu is doing.

The other big concern is the possibility of a slowdown in the Chinese economy. Though this would put a dent in Baidu's revenue, it still doesn't justify the company's low price. Baidu has a much bigger market to capture with small- and medium-sized businesses in China than Google does globally, but trades for only 20 times earnings. Google has more tame growth prospects, and yet it trades at a 30% premium to Baidu. That just doesn't add up.

National Oilwell Varco
NOV supplies all the nuts and bolts needed by the oil and gas industry to extract energy from the earth. Though the earnings report from the first quarter disappointed Wall Street, the company's backlog shows that there is growing demand to upgrade the world's aging oil rig fleet.

That, combined with the company's ubiquity in the industry and the fact that any up-tick in energy prices will be good for NOV shareholders, means that the company's best days are probably ahead of it. Trading at just 12 times earnings, and offering a fair 1.5% dividend yield, this is a very safe pick for any investor's retirement portfolio.

Want to know more?

To help determine if National Oilwell Varco could be a good fit for your portfolio, you're invited to check out The Motley Fool's premium research report featuring in-depth analysis on whether NOV is a buy today. For instant access to this valuable investor's resource, simply click here now to claim your copy.

Thursday, October 17, 2013

Yahoo: The Big Picture

Even if a company's losing a tremendous amount of market share in the US, it's imperative to also consider the company's global presence as well, writes MoneyShow's Jim Jubak, also of Jubak's Picks.

What's Yahoo (YHOO) worth?

Depends on whether you're looking at the company as a potential turnaround that's losing market share to aggressive competitors, or whether you see it as a way to get in on the growth of one of China's biggest e-commerce companies.

From the first perspective, Yahoo is an over-valued company, in my opinion, at a market cap of $33.8 billion.

From the second point of view, Yahoo is an under-valued company, in my opinion, at a market cap of $33.8 billion.

In reality, of course, Yahoo is a mix of these companies. And frankly, that mix is, at current prices, reasonably attractive—if you share my view of what is going on in the fiercely competitive Chinese Internet market.

Yahoo's third quarter results, released Tuesday, October 15, were ugly. Revenue fell 0.7%, was down 5% year over year. (That was in line with analyst estimates.) Operating income fell to $93 million from $152 million.

Ugly, but neither unexpected, nor particularly worrying for a turnaround. CEO Marissa Mayer has been on an acquisition drive, buying 19 companies since she took the helm in July 2012, in order to add users (by buying Tumblr), to increase engagement (by buying newsreader Summly), and to push Yahoo deeper into mobile (by buying Stamped and Jybe). With money going into more employees, and more pay for employees, and into R&D, it's certainly to be expected that operating income would take a hit.

What isn't necessarily expected and should raise questions about how difficult this turnaround will be, and the likely return on Yahoo's investment—of shareholder dollars, remember—in this turnaround, is the continued loss of market share in search and online ads.

Yahoo's share of the search market continues to fall. (Yahoo's search business is operated by Microsoft under a partnership between the two companies.) According to comScore, in September, Yahoo's share of the US search market fell to just 11.3%, matching the company's all-time low from July.

And, as you'd expect with falling market share in search, comes falling ad revenue from search. Revenue from the search business (after payments to Microsoft (MSFT)) fell 8% to $435 million. And market research group eMarketer, projects that Yahoo's share of the overall ad search market will drop to 6.2% in 2013 from 6.6% in 2012.

If you look deeper into the trends, the numbers get more disturbing. Yahoo's revenue from search is falling, even as the overall advertising spend on search is climbing, with projections pointing toward 13.2% growth in 2012.

It's in the numbers for revenue from display ads that things start to look really worrying, though. Display advertising, which accounts for about 40% of Yahoo's ad sales, fell 7% from the third quarter of 2012. That continues a long-term trend that has seen Yahoo, once the biggest seller of display ads, losing ground to competitors year after year. eMarketer projects that Yahoo's share of the display ad market will fall to 7.7% in 2013 from 8.6% in 2012 as Google (GOOG) (old story) grows to 17.4% of the display ad market and Facebook's (FB) share (new story) climbs.

It doesn't help that, thanks to the lower prices commanded by mobile ads and the advent of new advertising exchanges that enable advertisers to buy placements across a variety of Web sites with one electronic order, prices of ads for all players are under pressure. The number of ads Yahoo sold last quarter climbed by 1%, but the price per ad fell 7%.

All this ads up to a rather challenging picture. Yahoo's share of the total US online ad market is projected to drop to 7.7% in 2013, from 8.6% in 2012, according to eMarketer. Google's share will climb to 41.1% from 40.9% and Facebook's share will go to 7.1% from 5.9%.

Yahoo may be able to turn these trends around with new search results pages and a new mobile search interface, but forget about quick.

No, if you're looking for quick and for an explanation of why Yahoo shares are up 108% over the last 12 months, I think you'll have to look at the impending initial public offering for Alibaba, China's biggest e-commerce company. Alibaba is estimated to have a 43% share of the $703 billion Chinese e-commerce market. In 2012, the company accounted for 70% of package deliveries in China, according to the company's CEO, Jack Ma.

That could actually be true. Started as a business-to-business e-commerce site, Alibaba has expanded to include Tmall (where companies sell to consumers) and Taobao (where consumers sell to other consumers). According to Morgan Stanley, the gross value of goods that moved through Alibaba exceeded the combined value of goods that moved through Amazon.com (AMZN) and eBay (EBAY) in 2012.

Alibaba is expected to go public in 2014 at a market valuation of somewhere in the neighborhood of $55 to $120 billion.

And Yahoo currently owns 24% of Alibaba.

At a market valuation of $55 billion, Yahoo's stake is worth $13.2 billion. At a market valuation of $120 billion, Yahoo's stake is worth $28.8 billion.

Now consider that Yahoo's total market cap, even after the stock has climbed 108% in the last 12 months, is just $33.8 billion. At the top end of the range for Alibaba's IPO, all the rest of Yahoo, after deducting the value of its stake in Alibaba, is yours for just $5 billion dollars.

You know what you get for $5 billion in the Internet sector? Nothing. Facebook's market cap is $125 billion today. Twitter, which is expected to launch its own IPO around November 15, will be valued around $20 billion, analysts project.

But if you're buying Yahoo for its Alibaba stake, the question of how much Alibaba will be worth at its IPO, and how much it will be worth, say, a year after that debut, is critical. (Yahoo will sell about 40% of its stake, according to the most recent IPO plan, in the offering. Which means it will still own about 14% of Alibaba after the IPO.)

Let me give you some context that suggests that buying Yahoo in the hope the IPO will value Alibaba at the high $120 billion end of the neighborhood isn't crazy. Alibaba's net income climbed 145% in the third quarter year over year to $717 million. (Yes, Alibaba is profitable. Twitter most emphatically isn't.) Revenue climbed 61% to $1.74 billion.

Even before receiving any funds from the IPO, Alibaba has been on an acquisition spree designed to take the company into the US market. In June, Alibaba bought sports retailer Fanatics, and in August, it bought a minority stake in ShopRunner, a company that provides two-day delivery from 80 US retailers. Back in China, it has bought a 28% piece of digital mapping company AutoNav, and an 18% share of Sina's (SINA) micro blogging site, Weibo.

Finally, just let me point out that Alibaba competitor Tencent Holdings (HK:700) (OP:TCEHY) with a dominant position in instant messaging in China, but a much smaller share of the ecommerce market, has a market cap of $101 billion.

$120 billion for an Alibaba post-IPO valuation does seem like a pricey neighborhood, but Alibaba is a company that could nonetheless wind up living there.

Full disclosure: I don't own shares of any of the companies mentioned in this post in my personal portfolio. When in 2010 I started the mutual fund I manage, Jubak Global Equity Fund, I liquidated all my individual stock holdings and put the money into the fund. The fund may or may not now own positions in any stock mentioned in this post. The fund did not own shares of any company mentioned as of the end of June. Fund holding Naspers does own a sizeable position in Tencent Holdings. For a full list of the stocks in the fund as of the end of June see the fund's portfolio here.

Wednesday, October 16, 2013

At Long Last, The Hotel Market Shows Signs Of Life

The dual headwinds of being both tied to discretionary consumer spending as well as being part of the real estate complex, made the hotel & resort sector one of the worst performers during the Great Recession. The resulting commercial real estate recovery wasn't necessarily kind to the hotel real estate investment trusts (REITs) as well. The sub-sector was left behind by many of its office, retail and medical property peers.

However, recent data points and rising business travel spending are finally beginning to push the hotel REITs upwards. For investors, the former beaten down and ignored sector could finally be a buy.

Rising RevPAR & Business Spending

The hotel operators are finally breathing a sigh of relief as several key metrics are now showing positive growth for the year, all of which should make their investors quite happy.

First, the industries key metric- revenue per available room or RevPAR- has been steadily improving since the sector's lows. According to commercial property brokerage house Jones Lang LaSalle (NYSE:JLL), RevPAR metrics came in at an average $102.99 for resorts at the end of August. This is nearly a $7 year-over-year improvement and sits closer to historical averages. RevPAR averages are expected to rise about 6% this year and in 2014, as business and leisure travel continues to rebound. Additionally, average hotel occupancies continue to increase and marked a 1.1% gain to sit at 67% total occupancy.

Secondly, deal making across all sectors of the lodging industry, both limited service and luxury, continues to rise as investors plow capital into the industries bargains. Data provided by researcher Real Capital Analytics showed that sales of limited-service hotels totaled $3.8 billion in the first half of the year. That's more than double the amount of 2012. All in all, this buying activity has also pushed up the average price per room by 21% to sit at $77,635. Meanwhile, the luxury resort sector has seen some blockbuster deals a! s well. For example, Luxury hotelier LaSalle Hotel Properties (NYSE:LHO) recently shelled out $184.5 million for a 260-room resort in Key West.

All things considered, these factors have nearly two-thirds (64%) of hotel owners believing that hotel values will rise in the coming year. This compares to 55% who held a similar view in first quarter of the year.

Booking A Room

With the lodging industry beginning to show some real signs of recovery, investors may want to take a bet on some of the hotel REITs and operators. Unfortunately, unlike many real estate subsectors, the hotel/lodging industry does not have its own broad ETF representing it. Investors need to go with individual picks. Here's some top names to consider.

Ashford Hospitality Trust (NYSE:AHT) continues to reinvent itself. At first, the company was just a provider of capital for other hotel owners. However, since the Great Recession, Ashford has moved into owning more properties directly. That includes its recent $90 million purchase for a resort in Key West. However, Ashford isn't done yet. The company is planning on spinning-out several of its high luxury and yielding properties as a spate company called Ashford Hospitality Prime. The new firm will feature a RevPAR of $140.20. That's sustainably higher than luxury rivals Sunstone Hotel Investors (NYSE: SHO) and Strategic Hotels & Resorts (NYSE:BEE). For investors, Ashford and Ashford Prime could be big winners over the longer term. AHT currently yields 3.7%.

Focusing on upscale extended-stay hotels and premium-branded, select-service hotels, Chatham Lodging Trust (NASDAQ:CLDT) could be another interesting bet for investors. The hotelier's occupancy rate continues to be above average- at over 80%. This occupancy is also helping drive critical RevPAR growth and revenues. CLDT is expected to see a 20% jump in its revenues this year. Meanwhile, shares trade at cheap metrics and provide a juicy 4.5% monthly dividend yield.

Finally, for investors looking for a different way to play the return of hotel traffic, the owner/developer partners might be a better choice. These companies provide the capital and then earn fees by managing or franchising the actual property. The trio of Intercontinental Hotels Group (NYSE:IHG), Choice Hotels International (NYSE:CHH) and Wyndham Worldwide Corporation (NYSE:WYN) all prov! ide a chance to play the "brand names" in hotels, while snagging some dividends.

The Bottom Line

After feeling some of the worst effects of the global real estate meltdown, the hotel and lodging sector is coming back with a vengeance. Critical data points- such as RevPAR- are all moving upwards. For investors, hotel REITs could be some of the best real estate plays going into 2014.

Disclosure - At the time of writing, the author did not own shares of any company mentioned in this article.

Tech stocks: Yahoo climbing, eBay, IBM earnings…

Yahoo shares are up 2% in pre-market trading after analysts raised their price targets on the tech giant.

Reuters reports the reason for the optimism is Yahoo's decision to hold on to a larger stake in e-commerce company Alibaba. The company holds a 24% stake in Alibaba, and plans to hold on to more shares than analysts forecast.

The news follows Yahoo's third-quarter earnings report Tuesday, which showed another dip in quarterly revenue, but earnings that topped Wall Street estimates. The company raked in $1.08 billion in revenue, down 1% from the same time last year.

Meanwhile, two more big names report third-quarter earnings at the close of the markets on Wednesday. International Business Machines (IBM) is forecast to report an earnings per share of $3.96 off revenue of $24.8 billion. During its second quarter, IBM's revenue dipped 3%, but earnings per share soared 8% compared to the same time last year. Shares of IBM are up 9 cents.

Also reporting this afternoon is eBay. Wall Street is anticipating $3.9 billion in revenue for the quarter and an earnings per share of 63 cents. Shares of eBay are currently up 0.3%.

Last week, eBay announced it was dipping into Amazon Prime territory by offering free two-day shipping to shoppers of select retailers, including Levis, Aeropostale and Sports Authority. The test program follows Amazon unveiling a new "Login and Pay with Amazon" feature, which serves as a direct competitor to the eBay-owned payment service PayPal.

Finally, new details have emerged on the timing of Twitter's initial public offering. The company revealed it will trade on the New York Stock Exchange, launching its roadshow to entice investors on October 28.

According to CNBC, Twitter shares are slated to make their NYSE debut on November 15.

Follow Brett Molina on Twitter: @bam923.

Monday, October 14, 2013

Teradata shares drop after hours on cut outlook

SAN FRANCISCO (MarketWatch) — Teradata Corp. shares fell late Monday after the data-services company cut its outlook for the year.

Earnings Wall Earnings Wall

Discuss key earnings announcements as events unfold. Learn more

Key reports we're watching right now:
YHOO | KO | JNJ | INTC | CSX | C

/conga/story/misc/earnings_wall_threewide.html 282934

Shares of Teradata (TDC)  fell 11% to $46.65 on heavy volume after the company said it now expects adjusted full-year earnings of $2.70 to $2.80 a share. Analysts surveyed by FactSet expect earnings of $2.85 a share.

Teradata also expects adjusted third-quarter earnings of 69 cents to 70 cents a share on revenue of $665 million. Analysts forecast 69 cents a share on revenue of $700 million.

Demand Media Inc. (DMD)  shares declined 0.3% to $5.84 in light volume after the company said it had accepted the resignation of its chief executive, Richard Rosenblatt, effective Oct. 31.

Yahoo Inc. (YHOO)  said late Thursday it will accept questions from the public during its earnings call late Tuesday that are tweeted with the hashtag #YHOOearnings. Shares rose less than 0.1% to $34.02 in moderate volume.

Shares of Resource Capital Corp. (RSO)  declined 3.8% to $5.82 in moderate volume after the real-estate investment trust said it would launch a $100 million offering in notes due 2018.

Saturday, October 12, 2013

5 Stocks Insiders Are Scooping Up

DELAFIELD, Wis. (Stockpickr) -- Corporate insiders sell their own companies' stock for a number of reasons.

>>5 Stocks Poised for Breakouts

They might need the cash for a big personal purchase such as a new house or yacht, or they might need the cash to fund a charity. Sometimes they sell as part of a planned selling program that they have put in place for diversification purposes, which allows them to sell stock in stages instead of selling all at one price.

Other times they sell because they think their stock is overvalued and the risk/reward is no longer attractive. Some even dump their own stock because they have inside knowledge that a competitor is eating their lunch and stealing market share.

But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

The key word in that last statement is "think." Just because a corporate insider thinks his or her stock is going to trade higher, that doesn't mean it will play out that way. Insiders can have all the conviction in the world that their stock is a buy, but if the market doesn't agree with them, the stock could end up going nowhere. Also, I say "usually" because sometimes insiders are loaned money by the company to buy their own stock. Those loans are often sweetheart deals and shouldn't be viewed as organic insider buying.

>>5 Hated Earnings Stocks You Should Love

At the end of the day, its large institutional money managers running big mutual funds and hedge funds that drive stock prices, not insiders. That said, many of these savvy stock operators will follow insider buying activity when they agree with the insider that the stock is undervalued and has upside potential. This is why it's so important to always be monitoring insider activity, but it's twice as important to make sure the trend of the stock coincides with the insider buying.

Recently, a number of companies' corporate insiders have bought large amounts of stock. These insiders are finding some value in the market, which warrants a closer look at these stocks. Here's a look at five stocks whose insiders have been doing some big buying per SEC filings.

International Speedway

One stock that insiders are loading up on here is International Speedway (ISCA), an owner of major motorsports entertainment facilities and promoter of motorsports themed entertainment activities in the U.S. Insiders are buying this stock into weakness, since shares are off 10% during the last three months.

>>5 Rocket Stocks Ready for Blastoff

International Speedway has a market cap of $1.42 billion and an enterprise value of $1.52 billion. This stock trades at a premium valuation, with a trailing price-to-earnings of 26.89 and a forward price-to-earnings of 19.72. Its estimated growth rate for this year is -4%, and for next year it's pegged at 6.9%. This is not a cash-rich company, since the total cash position on its balance sheet is $163.37 million and its total debt is $276.48 million.

The CEO just bough 7,000 shares, or about $233,000 worth of stock, at $33.25 a share. The president also just bough 7,000 shares, or about $233,000 worth of stock, at $33.25 a share.

From a technical perspective, ISCA is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently spiked lower from its high of $33.58 to its low of $30.14 a share. During that move, shares of ISCA have been consistently making lower highs and lower lows, which is bearish technical price action.

If you're bullish on ISCA, then I would look for long-biased trades as long as this stock is trending above both its 200-day at $31.88 and its 50-day at $32.22 and then once it breaks out above some near-term overhead resistance at $33.58 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 122,071 shares. If we get that move soon, then ISCA will set up to re-test or possibly take out its next major overhead resistance levels at $34.90 to its 52-week high at $35.77 a share.

ChemoCentryx

Another biopharmaceutical player that insiders love here is ChemoCentryx (CCXI), which is engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Insiders are buying this stock into big time weakness, since shares are off sharply by 51% in 2013.

>>5 Trades to Take in the Health Care Sector

ChemoCentryx has a market cap of $226.59 million and an enterprise value of $96.59 million. This stock trades at a premium valuation, with a price-to-sales of 32.64 and a price-to-book of 1.44. Its estimated growth rate for this year is 8.8%, and for next year it's pegged at -16.5%. This is a cash-rich company, since the total cash position on its balance sheet is $129.77 million and its total debt is just $618,000.

A beneficial owner just bought 109,425 shares, or about $601,000 worth of stock, at $5.49 per share.

From a technical perspective, CCXI is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last three months, with shares plunging lower from its high of $14.75 to its recent low of $5.10 a share. During that downtrend, shares of CCXI have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of CCXI have now moved into oversold territory, since its current relative strength index reading is 24.98. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from.

If you're in the bull camp on CCXI, then look for long-biased trades as long as this stock is trending above its recent low of $5.10 and then once it breaks out above some near-term overhead resistance at $5.90 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 439,942 shares. If that breakout triggers soon, then CCXI will set up to re-test or possibly take out its next major overhead resistance levels at $6.45 to $7 a share. Any high-volume move above $7 will then give CCXI a chance to re-fill some of its previous gap down zone from September that started at $8.46 a share.

Achillion Pharmaceuticals

One biopharmaceutical player that insiders are jumping into big here is Achillion Pharmaceuticals (ACHN), which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. Insiders are buying this stock into massive weakness, since shares are off sharply by 67% so far in 2013.

>>5 Stocks Spiking on Big Volume

Achillion Pharmaceuticals has a market cap of $246.43 million and an enterprise value of $136.34 million. This stock trades at a premium valuation, with a price-to-sales of 2,244 and a price-to-book of 1.50. Its estimated growth rate for this year is -14.1%, and for next year it's pegged at -15.1%. This is a cash-rich company, since the total cash position on its balance sheet is $133.82 million and its total debt is just $525,000.

A beneficial owner just bought 2.8 million shares, or about $8.35 million worth of stock, at $2.96 to $3.01 per share.

From a technical perspective, ACHN is currently trending just below both its 50-day and 200-day moving averages, which is bearish. This stock recently gapped down sharply from around $7.50 to below $3 a share with heavy downside volume. Following that gap down, shares of ACHN have continued to trend lower with the stock printing a new 52-week low today. This move has pushed shares of ACHN into extremely oversold territory, since its current relative strength index reading is 18.08. Oversold can always get more oversold, but it's also an area where a stock can bounce sharply higher from if the buyers step back in.

If you're bullish on ACHN, then look for long-biased trades as long as this stock is trending above $2.50 and then once it breaks out above some near-term overhead resistance levels at $2.85 to $3 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 2.10 million shares. If that breakout triggers soon, then ACHN will set up to re-test or possibly take out its gap down day high of $3.62 a share.

Bridge Bancorp

One banking player that insiders are snapping up a solid amount of stock in here is Bridge Bancorp (BDGE), which provides commercial and consumer banking business, including saving and deposits from the consumers, commercial and real estate loans and homey equity loans. Insiders are buying this stock into modest strength, since shares are up 6.4% so far in 2013.

>>4 Stocks Under $10 in Breakout Territory

Bridge Bancorp has a market cap of $193 million and an enterprise value of $289.60 million. This stock trades at a fair valuation, with a trailing price-to-earnings of 14.75 and a forward price-to-earnings of 13.97. Its estimated growth rate for this year is 12.5%, and for next year it's pegged at 7.6%. This is not a cash-rich company, since the total cash position on its balance sheet is $40.82 million and its total debt is $137.91 million. This stock currently sports a dividend yield of 4.2%.

The CEO just bought 10,000 shares, or about $207,000 worth of stock, at $20.75 per share. A director also just bought 10,000 shares, or about $207,000 worth of stock, at $20.75 per share.

From a technical perspective, BDGE is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been trending sideways inside of a consolidation pattern for the last two months, with shares moving between $20.60 on the downside and $22.24 on the upside. Shares of BDGE have recently crossed back above both its 50-day and 200-day moving averages. That move is quickly pushing shares of BDGE within range of triggering a breakout trade above the upper-end of its recent range.

If you're bullish on BDGE, then look for long-biased trades as long as this stock is trending above some key near-term support levels at $21 or at $20.60 and then once it breaks out above some near-term overhead resistance at $22.24 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 30,922 shares. If that breakout hits, then BDGE will set up to re-test or possibly take out its 52-week high at $24.99 a share.

Lionbridge Technologies

One final name with decent insider buying is Lionbridge Technologies (LIOX), which provides a suite of language, content and testing solutions. Insiders are buying this stock into modest weakness, since shares are off 8.9% so far in 2013.

>>4 Hot Stocks to Trade (or Not)

Lionbridge Technologies has a market cap of $222.16 million and an enterprise value of $230.70 million. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 28.29 and a forward price-to-earnings of 14.60. Its estimated growth rate for this year is -63.2%, and for next year it's pegged at 257.1%. This is not a cash-rich company, since the total cash position on its balance sheet is $17.64 million and its total debt is $26.70 million.

A beneficial owner just bought 175,000 shares, or about $654,000 worth of stock, at $3.73 to $2.32 per share.

From a technical perspective, LIOX is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending for the last five months, with shares moving higher from its low of $2.16 to its recent high of $3.89 a share. During that uptrend, shares of LIOX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of LIOX within range of triggering a major breakout trade.

If you're bullish on LIOX, then look for long-biased trades as long as this stock is trending above some key near-term support levels at $3.46 or at $3.20 and then once it breaks out above some near-term overhead resistance levels at $3.80 to $3.89 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 208,575 shares. If that breakout triggers soon, then LIOX will set up to re-test or possibly take out its 52-week high at $4.25 a share. Any high-volume move above $4.25 will then give LIOX a chance to tag $5 to $6 a share.

To see more stocks with notable insider buying, check out the Stocks With Big Insider Buying portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:



>>5 Stocks Under $10 Making Big Moves



>>3 Huge Stocks on Traders' Radars



>>5 Stocks Set to Soar on Bullish Earnings

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.